Authors

Latest:

Preparing Nurses for Advanced Practice in Oncology and Palliative Care

Barbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.

Helena A. Yu, MD

Latest:

The Future of Tumor Agnostic Therapies in EGFRm m NSCLC

Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.

Helmut Schaider, MD

Latest:

Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Heloisa P. Soares, MD, UNM Comprehensive Cancer Center

Latest:

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Hendrik-Tobias Arkenau, MD, PhD

Latest:

Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.

Henricus de Koning, MD

Latest:

Dr. Henricus de Koning on Screening in NSCLC

Henry M. Kuerer, MD, PhD

Latest:

Dr Kuerer on Advancements in Neoadjuvant Systemic Therapies in Breast Cancer

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Henry M. Kuerer, MD, PhD, FACS

Latest:

Controversies and Clinical Trials for DCIS: Margins and Active Surveillance

The management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.

Henry M. Kuerer, MD, PhD, FACS, CMQ

Henry M. Kuerer, MD, is a Professor and Executive Director Breast Programs, MD Anderson Cancer Network, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Latest:

Dr Kuerer on the Safety, Feasibility of Omitting Surgery in Select Patients With HER2+, Triple-Negative Breast Cancer

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Herbert A. Eradat, MD

Latest:

Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Herbert B. Newton, MD, FAAN Advent Health Cancer Institute

Latest:

Management of Neurofibromatosis Type 1 with Plexiform Neurofibromas (NF1 with PNs)

Herbert I. Hurwitz, MD, Duke University Medical Center

Hernan Vargas, MD, FACS

Latest:

Dr. Vargas on the Utility of Sentinel Node Biopsy in Breast Cancer

Hernan Vargas, MD, FACS, a breast surgeon at Virginia Cancer Specialists, discusses the utility of sentinel lymph node biopsy in breast cancer.

Hervé Dombret, MD, Institut Universitaire d’Hématologie

Herve Tilly, MD, PhD

Latest:

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Hetty Carraway

Latest:

Dr. Carraway on Aza-Nucleoside Combinations in MDS

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

Hetty Carraway, MD

Latest:

Dr Carraway on Currently Available Treatment Options for AML

Hetty E. Carraway, MD, MBA, discusses current treatment strategies available for patients with acute myeloid leukemia.

Hideho Okada MD, PhD

Latest:

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Himisha Beltran, MD

Latest:

Dr Beltran on the Utility of HPN328 Regimens in Preclinical Mouse Models

Himisha Beltran, MD, discusses data from 2 preclinical immunocompetent mouse models evaluating the DLL3-targeted, half-life extended T-cell engager HPN328.